Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine

NCT07018700 is registered in ClinicalTrials.gov with Merz Therapeutics GmbH as lead sponsor.

NCT NCT07018700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine
Lead sponsor
Merz Therapeutics GmbH
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 21, 2025
Completion date
September 30, 2027
Enrollment
997 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine